



NOW APPROVED

**Evrysdi is proven to make a
difference in infants, children,
and adults with SMA¹**

In patients 2 months and older who exhibit a broad range of disease severity and functional ability

Indication

Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.

Important Safety Information

Interactions with Substrates of MATE Transporters


- Based on in vitro data, Evrysdi may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K, such as metformin
- Avoid coadministration of Evrysdi with MATE (multidrug and toxin extrusion) substrates. If coadministration cannot be avoided, monitor for drug-related toxicities and consider dosage reduction of the coadministered drug if needed

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

FOR HEALTHCARE PROFESSIONALS

THE SYMPTOMS OF SMA ARE CAUSED BY SMN PROTEIN DEFICITS

SMA is caused by insufficient levels of functional SMN protein throughout the body²



People with SMA rely on the limited functional protein produced by the *SMN2* gene

SMN protein deficiencies can have a widespread impact³

PEOPLE WITH SMA MAY FACE SEVERE CONSEQUENCES

In infantile-onset disease, most patients are not expected to survive



No more than ~25% of patients are expected to survive longer than 14 months without permanent ventilation¹



Patients who survive are not expected to attain the ability to sit independently¹

In later-onset disease, children and adults may face progressive loss of function



These patients may experience **motor function impairment**, which can impact daily function⁴



These patients may experience varying degrees of **limb weakness⁵**

¹ SMN=survival motor neuron.

THE EVRYSDI TRIAL PROGRAM WAS DESIGNED TO REFLECT THE REAL-WORLD POPULATION OF PEOPLE WITH SMA

The Evrysdi trial program is assessing efficacy and safety in a wide range of people with SMA^{1,6}

450+ PATIENTS^{1,6,7*}

with infantile-onset and later-onset SMA[†]



2 MONTHS OF AGE



60 YEARS OF AGE

- Efficacy data in patients 2 months to 25 years of age
- Safety data in patients 2 months to 60 years of age

With different levels of disease severity and functional ability¹

Both ambulatory and nonambulatory^{1,7}

With or without scoliosis (mild to severe)¹


Treatment naive and previously treated (evaluated for safety)^{7,8}

This is the first SMA trial program to include patients over 18 years of age, some of whom have severe scoliosis⁸

*Enrollment across 3 clinical trials.

†Infantile-onset SMA defined as Type 1 SMA; later-onset SMA defined as Type 2 or Type 3 SMA.

EVRYSDI IS BEING EVALUATED IN 3 CLINICAL TRIALS



Important Safety Information (continued)

Pregnancy

- In animal studies, administration of Evrysdi during pregnancy or throughout pregnancy and lactation resulted in adverse effects on development
- Based on animal data, advise pregnant women of the potential risk to the fetus. Pregnancy testing is recommended for females of reproductive potential prior to initiating Evrysdi. Advise female patients of reproductive potential to use effective contraception during treatment with Evrysdi and for at least 1 month after the last dose

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.



FIREFISH WAS DESIGNED TO ESTABLISH THE SAFETY AND EFFICACY OF EVRYSDI IN INFANTS WITH SMA



FIREFISH

2-part, multicenter, open-label trial in infantile-onset SMA (Type 1 SMA)^{1,8}

- Part 1 (n=21) was the exploratory, dose-finding portion
 - The first 4 enrollees received a lower dose (0.08 mg/kg) and did not have their dose increased before 12 months; all other enrollees (n=17) had their dose adjusted to the recommended dose (0.2 mg/kg) before 12 months
 - Efficacy was established on the ability to sit without support for at least 5 seconds as measured by Item 22 of the BSID-III gross motor scale and on the basis of survival without permanent ventilation
- In Part 2 (n=41), the primary endpoint was achievement of a motor milestone at 12 months, as measured by Item 22 of the BSID-III gross motor scale

BSID-III=Bayley Scales of Infant and Toddler Development-Third Edition.

Important Safety Information (continued)

Breastfeeding

- There is no data on the presence of Evrysdi in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Evrysdi and any potential adverse effects on the breastfed infant

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

EVRYSDI IS BEING STUDIED IN LATER-ONSET SMA AND PREVIOUSLY TREATED PATIENTS



SUNFISH

2-part, randomized, multicenter, placebo-controlled trial in later-onset SMA (Type 2/Type 3 SMA)^{1,8,9}

- Part 1 (n=51) was the exploratory, dose-finding portion and included both ambulatory (14% [n=7]) and nonambulatory patients (65% [n=33] sitters and 21% [n=11] nonsitters)
- Part 2 (n=180) was the confirmatory portion and included nonambulatory patients who had mild to severe scoliosis (67% [n=120] total, 32% [n=57] of whom had severe scoliosis)
 - Participants were randomized 2:1 to receive either the recommended dose of Evrysdi established in Part 1 or placebo for 12 months before switching to Evrysdi
 - The primary endpoint was mean change from baseline in motor function score at 12 months, as measured by MFM-32
 - Mean baseline MFM-32 total score was 46.1



JEWELFISH

Single-arm, open-label, exploratory trial with 174 patients enrolled (Type 1/Type 2/Type 3 SMA)^{6,7}

- This study is investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of Evrysdi in both ambulatory and nonambulatory patients (9% [n=16] walkers, 56% [n=97] sitters, 32% [n=55] nonsitters, and 3% [n=6] unknown)
- Participants have received previous treatment with approved or investigational therapies including an *SMN2*-splicing modifier (≥90 days prior to screening) or gene replacement therapy (≥12 months prior to screening)

INFANTS ACHIEVED THE ABILITY TO SIT WITHOUT SUPPORT FOR AT LEAST 5 SECONDS

This important motor milestone was measured by BSID-III¹

MILESTONE ACHIEVEMENT AFTER 12 MONTHS OF TREATMENT (Recommended-dose cohort; n=17)*

FIREFISH Part 1

41%
(7/17)

of infants were sitting without support for ≥5 seconds

As measured by Item 22 of the BSID-III gross motor scale[†]

*Patients (n=21) were enrolled in 1 of 2 dose cohorts. Patients in the higher-dose cohort (n=17) had their dose adjusted to the recommended dose of 0.2 mg/kg before 12 months of treatment, while patients in the low-dose cohort (n=4) did not.

†Patients who died or who were withdrawn from the study are considered to be nonresponders (n=2 at Month 12).⁹ BSID-III=Bayley Scales of Infant and Toddler Development-Third Edition.

Important Safety Information (continued)

Potential Effects on Male Fertility

- Male fertility may be compromised by treatment with Evrysdi. Counsel male patients on the potential effects on fertility. Male patients may consider sperm preservation prior to treatment

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

EVRYSDI HELPED INFANTS SURVIVE WITHOUT PERMANENT VENTILATION

Results after at least 12 months of treatment demonstrated efficacy during a critical time for infants with SMA¹

AFTER TREATMENT WITH EVRYSDI (All-patients cohort; n=21)

FIREFISH Part 1

90%
(19/21)

of infants were alive without the need for permanent ventilation and reached ≥15 months of age*

After 12 months of treatment

81%
(17/21)

of infants were alive without the need for permanent ventilation and reached ≥28 months of age*

After 23 months of treatment

*Permanent ventilation defined as requiring a tracheostomy or >21 consecutive days of either noninvasive ventilation (≥16 hours per day) or intubation, in the absence of an acute reversible event.




EVRYSDI DEMONSTRATED EFFICACY IN THOSE WITH VARYING LEVELS OF DISEASE SEVERITY

Evrysdi met its primary endpoint with significantly greater change in motor function score vs placebo at Month 12, as measured by MFM-32¹

CHANGE IN MFM-32 SCORE OVER 12 MONTHS OF TREATMENT**

SUNFISH Part 2



- 1.55-point difference (95% CI: 0.30, 2.81) between the means ($P=0.0156$)[†]
- The MFM-32 is a 32-item scale designed to assess various motor functions in people with neuromuscular disorders. The scale measures motor function abilities that relate to important daily functions^{10,11}

These results demonstrated a clinically meaningful difference for patients treated with Evrysdi compared with placebo¹

*The least square (LS) mean difference for change from baseline in MFM-32 score (95% CI).

[†]Based on the missing-data rule for MFM-32, 6 patients (n=5 for Evrysdi; n=1 for placebo) were excluded from the analysis.


[‡]The mixed-model repeated-measures analysis included the change from baseline total score as the dependent variable; independent variables included the baseline total score, treatment group, time, treatment-by-time interaction, and the randomization stratification variable of age group (2 to 5, 6 to 11, 12 to 17, and 18 to 25 years). The MFM-32 total score was calculated according to the user manual as a percentage of the maximum score for the scale (ie, sum of the 32 item scores divided by 96 and multiplied by 100).
MFM-32=Motor Function Measure-32 Items.

EVRYSDI HELPED IMPROVE UPPER LIMB FUNCTIONS MEASURED BY RULM

Evrysdi provided a clinically meaningful difference for patients, as demonstrated by the statistically significant improvements in RULM score observed after 12 months^{1,8}

CHANGE IN RULM SCORE OVER 12 MONTHS OF TREATMENT^{1*†}

SUNFISH Part 2



- 1.59-point difference (95% CI: 0.55, 2.62) between the means ($P=0.0469$)[†]
- RULM is a thorough measurement of upper limb function for a broad range of people with SMA that is able to capture mobility in people with varying degrees of muscle weakness²

*The least square mean difference for change from baseline in RULM score (95% CI).

[†]Based on the missing-data rule for RULM, 3 patients (n=1 for Evrysdi; n=2 for placebo) were excluded from the analysis.

[‡]The mixed-model repeated-measures analysis included the change from baseline total score as the dependent variable; independent variables included the baseline total score, treatment group, time, treatment-by-time interaction, and the randomization stratification variable of age group (2 to 5, 6 to 11, 12 to 17, and 18 to 25 years).
RULM=Revised Upper Limb Module.

Important Safety Information (continued)

Hepatic Impairment

- The safety and efficacy of Evrysdi in patients with hepatic impairment have not been studied
- Because Evrysdi is predominantly metabolized in the liver, hepatic impairment may potentially increase the exposures to Evrysdi. Avoid use of Evrysdi in patients with impaired hepatic function

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.



THE SAFETY PROFILE OF EVRYSDI HAS BEEN EVALUATED IN 3 CLINICAL TRIALS



Safety information in infants with Type 1 SMA from the FIREFISH trial^{1,8}

ADVERSE REACTIONS OCCURRING IN ≥10% OF INFANTS RECEIVING EVRYSDI IN FIREFISH PART 1 AND PART 2 (N=62)

Adverse reaction	Incidence
Upper respiratory tract infection (URTI)*	60%
Fever	40%
Rash†	26%
Pneumonia	26%
Constipation	18%
Diarrhea	15%
Vomiting	15%

*Includes all URTI-basketed events. Most common events (≥10%) in the basket include URTI, nasopharyngitis, respiratory tract infection, and rhinitis.

†Includes rash, erythema, rash maculopapular, dermatitis, rash papular, dermatitis allergic, and folliculitis.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

EVRYSDI DEMONSTRATED CONSISTENT SAFETY IN LATER-ONSET SMA



Safety information in children and adults with Type 2 or Type 3 SMA from Part 2 of the SUNFISH trial¹

ADVERSE REACTIONS OCCURRING IN ≥5% OF CHILDREN AND ADULTS RECEIVING EVRYSDI AND WITH AN INCIDENCE OF ≥5% COMPARED WITH PLACEBO IN SUNFISH PART 2 (n=180)

Adverse reaction	Evrysdi (n=120)	Placebo (n=60)
Fever*	22%	17%
Diarrhea	17%	8%
Rash†	17%	2%
Mouth and aphthous ulcers	7%	0%
Arthralgia	5%	0%
Urinary tract infection [‡]	5%	0%

- The most common adverse reactions reported in ≥10% of patients receiving Evrysdi and at an incidence greater than placebo were fever, diarrhea, and rash
- No patients discontinued Evrysdi as a result of treatment-related adverse reactions during the 12 months on treatment in the FIREFISH and SUNFISH trials⁸



Initial safety findings from JEWELFISH have been consistent with the safety in FIREFISH and SUNFISH⁷

The trial includes participants who were previously treated with investigational or approved SMA therapies.⁶

*Includes pyrexia and hyperpyrexia.

†Includes rash, erythema, rash maculopapular, rash erythematous, rash papular, dermatitis allergic, and folliculitis.

‡Includes urinary tract infection and cystitis.



EVRYSDI IS THE FIRST AND ONLY AT-HOME TREATMENT FOR SMA



Liquid solution¹



Taken via oral syringe, either by mouth or feeding tube¹



Self-administered or delivered with help from caregiver¹

Select dosing instructions¹

Please refer your patients or their caregivers to the Instructions for Use for complete information on how to take or administer Evrysdi.

Instruct patients to:



Take their medication at approximately the same time each day after a meal or breastfeeding

Evrysdi cannot be mixed with formula or milk



Drink water after administration to ensure the drug has been completely swallowed

Important Safety Information (continued)

Most Common Adverse Reactions

- The most common adverse reactions in later-onset SMA (incidence in at least 10% of patients treated with Evrysdi and more frequent than control) were fever, diarrhea, and rash
- The most common adverse reactions in infantile-onset SMA were similar to those observed in later-onset SMA patients. Additionally, adverse reactions with an incidence of at least 10% were upper respiratory tract infection, pneumonia, constipation, and vomiting

You may report side effects to the FDA at **1-800-FDA-1088** or **www.fda.gov/medwatch**. You may also report side effects to Genentech at **1-888-835-2555**.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

THE RIGHT DOSE IS DIFFERENT FOR EACH PATIENT

Dosing for infants, children, and adults depends on age and weight¹

2 months to <2 years	Recommended once-daily dose	
	0.2 mg/kg x weight (kg)	
≥2 years	Weight	Recommended once-daily dose
	<20 kg	0.25 mg/kg x weight (kg)
	≥20 kg	5 mg



Administration guidance¹

- If a patient misses a planned dose and ≤6 hours have passed, he or she should take Evrysdi as soon as possible, then resume the usual dosing schedule on the next day
- If a patient misses a planned dose and >6 hours have passed, he or she should skip the missed dose, then take the next dose at the regularly scheduled time on the next day
- If a dose is not fully swallowed or vomiting occurs after administration, the patient should not take or administer another dose to make up for the lost dose; he or she should wait until the following day to take the next dose at the regularly scheduled time




Storage guidance¹

- The liquid solution should be refrigerated (never frozen) in the original amber bottle to protect from light, and should be stored in an upright position with the cap tightly closed to avoid spillage

It is recommended that you advise your patients or their caregivers about how to prepare and administer Evrysdi before the first daily dose.

EVRYSDI IS DESIGNED TO ADDRESS THE UNDERLYING CAUSE OF SMA

Evrysdi is an *SMN2*-splicing modifier¹



MOA=mechanism of action.

EVRYSDI LED TO AN INCREASE IN SMN PROTEIN

In clinical trials, treatment increased and sustained functional SMN protein levels¹

CHANGE IN SMN PROTEIN LEVELS
AS MEASURED IN THE BLOOD



>2-fold increase

in median SMN protein levels observed at 4 weeks and sustained through ≥ 12 months of treatment across all SMA types

Important Safety Information (continued)

Interactions with Substrates of MATE Transporters

- Based on in vitro data, Evrysdi may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K, such as metformin
- Avoid coadministration of Evrysdi with MATE (multidrug and toxin extrusion) substrates. If coadministration cannot be avoided, monitor for drug-related toxicities and consider dosage reduction of the coadministered drug if needed

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.



INFANTS IN FIREFISH PART 1 HAD VARYING LEVELS OF DISEASE SEVERITY

Infant ages, disease progression rate, and baseline motor function were designed to reflect those seen in a real-world setting^{1,8}

PART 1 BASELINE DEMOGRAPHICS (ALL INFANTS; n=21)

Patient characteristics	
Median age at onset, months (range)	2.0 (0.9-3.0)
Median age at enrollment, months (range)	6.7 (3.3-6.9)
Median weight, kg (range)	6.7 (5.2-8.9)
Motor function assessment scores	
CHOP INTEND; median (range)	24.0 (10.0-34.0)
HINE-2; median (range)	1.0 (0.0-3.0)

Infants in FIREFISH received their first dose of Evrysdi at a median age of 6.7 months¹

CHOP INTEND=Children's Hospital of Philadelphia Infant Test of Neurological Disorders; HINE-2=Hammersmith Infant Neurological Examination Module 2.

Important Safety Information (continued)

Pregnancy

- In animal studies, administration of Evrysdi during pregnancy or throughout pregnancy and lactation resulted in adverse effects on development
- Based on animal data, advise pregnant women of the potential risk to the fetus. Pregnancy testing is recommended for females of reproductive potential prior to initiating Evrysdi. Advise female patients of reproductive potential to use effective contraception during treatment with Evrysdi and for at least 1 month after the last dose

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

SUNFISH PART 2 INCLUDED A BROAD RANGE OF PARTICIPANTS DESIGNED TO REFLECT THE REAL-WORLD SMA POPULATION

SUNFISH was purposefully designed to include older children and adults with complications, such as contractures and severe scoliosis^{1,8*}

	Evrysdi (n=120)	Placebo (n=60)
Patient characteristics		
SMA Type, % (n)		
Type 2	70.0% (84)	73.3% (44)
Type 3	30.0% (36)	26.7% (16)
Disease severity		
Mean age at onset, months (SD)	14.1 (8.4)	18.5 (21.1)
Scoliosis, % (n)		
Yes	63.3% (76)	73.3% (44)
>40° curvature	28.3% (34)	38.3% (23)
Surgery for scoliosis before screening, % (n)		
Yes	24.2% (29)	28.3% (17)
No	52.5% (63)	55.0% (33)
Motor function assessment scores at baseline		
MFM-32 total score, median (min-max)	46.9 (16.7-71.9)	47.9 (17.7-71.9)
n	115	59
RULM total score, median (min-max)	19.0 (3.0-36.0)	20.0 (9.0-38.0)
n	119	58
HFMSE total score, median (min-max)	14.0 (0.0-48.0)	13.0 (2.0-43.0)
n	120	60

*The overall baseline demographic characteristics were well balanced between Evrysdi and placebo groups, with the exception of an imbalance of patients with scoliosis (63% of patients in the Evrysdi arm and 73% of patients in the placebo control).

HFMSE=Hammersmith Functional Motor Scale Expanded; MFM-32=Motor Function Measure-32 Items; RULM=Revised Upper Limb Module.



MySMA SUPPORT IS HERE FOR YOUR PATIENTS

MySMA Support is a support service that informs patients about Evrysdi and helps them understand their insurance coverage and financial assistance options



Neurological Rare Disease Therapeutic Area Manager (NRD TAM)

The local, dedicated support resource for healthcare providers and their staff who answers questions about Genentech's approved products and services.



Partnership and Access Liaison (PAL)

The local, main point of contact from Genentech who supports people living with SMA. PALs are here to answer questions about Evrysdi and refer your patients to helpful resources. PALs can also help them understand their insurance and financial support options.

A PAL is not a part of the patient's medical team and is not a substitute for their healthcare provider. PALs do not provide medical advice. The patient's healthcare provider should always be the main resource for any questions about the patient's health and medical care.



Case Manager (CM)

A Case Manager partners closely with PALs and healthcare providers to help people living with SMA understand the health insurance process and identify potential financial support options for Genentech's approved products.



Accredo*

Accredo is the only specialty pharmacy that prepares and ships Evrysdi directly to your patients each month. Although Accredo is not a part of Genentech, it is an important part of the MySMA Support team.

*Accredo Health Group, Inc., is an Express Scripts specialty pharmacy. Accredo is not part of Genentech and maintains independence in its operations as a specialty pharmacy and in its role as a healthcare provider.

Important Safety Information (continued)

Breastfeeding

- There is no data on the presence of Evrysdi in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Evrysdi and any potential adverse effects on the breastfed infant

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

HELP PATIENTS RECEIVE THE TREATMENT THEY NEED

Financial assistance offerings (by program)

Evrysdi Co-pay Program*

Patients who qualify can receive up to \$25,000 in assistance per 12-month period. They pay as little as \$5 per prescription co-pay or co-insurance until the annual limit is reached.

Referral to independent co-pay assistance foundation†

If eligible publicly or commercially insured patients have difficulty paying for their co-pay, co-insurance or other out-of-pocket (OOP) costs, a Case Manager can refer them to an independent co-pay assistance foundation supporting SMA.

The Genentech Patient Foundation

The Genentech Patient Foundation gives free Genentech medicine to people who don't have insurance coverage or who have financial concerns and meet eligibility criteria. The Genentech Patient Foundation helps:

- Uninsured patients with incomes under \$150,000[‡]
- Insured patients without coverage for a Genentech medicine with incomes under \$150,000[‡]
- Insured patients with coverage for a Genentech medicine
 - With unaffordable out-of-pocket costs
 - Who have pursued available financial assistance
 - With household size and income within certain guidelines (see table below)

Household Size	Annual Income
1	Less than \$75,000
2	Less than \$100,000
3	Less than \$125,000
4	Less than \$150,000

*This Evrysdi Co-pay Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid, or any other federal or state government program to pay for their medications are not eligible. Under the Program, the patient will pay a co-pay. After reaching the maximum Program benefit, the patient will be responsible for all out-of-pocket costs. All participants are responsible for reporting the receipt of all Program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this Program. This Program is void where prohibited by law. Genentech reserves the right to rescind, revoke, or amend the Program without notice at any time. Additional eligibility criteria apply. See full terms and conditions at www.evrysidicopay.com.

†Genentech does not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from Genentech. The foundations to which we refer patients are not exhaustive or indicative of Genentech's endorsement or financial support. There may be other foundations to support the patient's disease state.

‡For all patient types, add \$25,000 for each extra person in households larger than 4 people.



Other support programs

Evrysdi Start Program*

Program Overview: The Evrysdi Start Program may help people with SMA begin treatment as soon as possible by providing short term, free medication. The Evrysdi Start Program is available for insured people with SMA who have been prescribed Evrysdi and are experiencing a delay in insurance approval. Eligible people with SMA may receive up to 2 free 30-day supplies of Evrysdi.

How it works: If you believe your patient qualifies for Evrysdi Start Program, please submit the completed Evrysdi Start Form and check the Starter section (Section 6) of the Prescriber Service Form. Valid Patient Consent Form is also required to enroll a patient into the Evrysdi Start Program. For more information, please contact your Evrysdi representative.

Contact MySMA Support at (833) 387-9734
(Monday-Friday, 9 AM to 8 PM ET)

*The Evrysdi Start Program provides eligible patients who have experienced an insurance coverage delay with a one-time free supply of Evrysdi, 60 mg powder for oral solution. There is no purchase of obligation by virtue of a patient's receipt of the free supply. Requests for the Evrysdi Start Program cannot be processed without a completed and signed 1) Evrysdi Prescriber Service Form and 2) Patient Consent Form. Patients must be prescribed Evrysdi for an on-label use. Free product via the Evrysdi Start Program will be available through Genentech. Neither the prescriber, the pharmacies, nor any patients receiving free product via the Evrysdi Start Program may seek reimbursement or credit for all or any part of the benefit received by the patient through this offer from any insurer, health plan, or government program. The Evrysdi Start Program cannot be counted towards any Out-of-Pocket costs under any plan (such as true Out-of-Pocket cost [TrOOP] under a Medicare Part D prescription drug plan). The Evrysdi Enrollment Team may notify the patient's insurer that the patient is receiving a free supply of product from the Program. Prescribers may not advertise or otherwise use the program as a means of promoting their services or Genentech's products to patients. This program is void where prohibited by law and may not be used in or by residents of restricted states, if applicable. The free supply may not be sold, purchased or traded or offered for sale, purchase or trade. This program is not a benefit plan. Genentech reserves the right to discontinue or modify the terms of this program at any time, without notice.

REFERENCES

1. Evrysdi™ (risdiplam) Prescribing Information. Genentech, Inc.
2. Hamilton G, Gillingwater TH. Spinal muscular atrophy: going beyond the motor neuron. *Trends Mol Med.* 2013;19(1):40-50.
3. Park G-H, Maeno-Hikichi Y, Awano T, et al. Reduced survival of motor neuron (SMN) protein in motor neuronal progenitors functions cells autonomously to cause spinal muscular atrophy in model mice expressing the human centromeric (*SMN2*) gene. *J Neurosci.* 2010;30(36):12005-12019.
4. Cruz R, Lenz M, Belter L, et al. The Voice of the Patient Report for Spinal Muscular Atrophy. Cure SMA website. Published January 10, 2018. <https://curesma.wpengine.com/wp-content/uploads/2018/01/SMA-VoP-for-publication-1-22-2018.pdf>. Accessed April 13, 2020.
5. Farrar MA, Park SB, Vucic S, et al. Emerging therapies and challenges in spinal muscular atrophy. *Ann Neurol.* 2017;81(3):355-368.
6. A study of risdiplam (Ro7034067) in adult and pediatric participants with spinal muscular atrophy (Jewelfish). ClinicalTrials.gov. <https://clinicaltrials.gov/ct2/show/NCT03032172>. Accessed April 13, 2020.
7. Chiriboga CA, Bruno C, Duong T, et al. JEWELFISH: safety and pharmacodynamic data in non-naïve patients with spinal muscular atrophy receiving treatment with risdiplam. Presentation at: 2020 Virtual SMA Conference; June 8-12, 2020; Virtual.
8. Data on file. Genentech, Inc.
9. Day JW, Anoussamy M, Baranello G, et al. SUNFISH part 1: 24-month safety and exploratory outcomes of risdiplam (RG7916) treatment in patients with Type 2 or 3 spinal muscular atrophy (SMA). Presentation at: 2020 Virtual SMA Conference; June 8-12, 2020; Virtual.
10. Bérard C, Payan C, Hodgkinson I, et al, and the MFM Collaborative Study Group. A motor function measure scale for neuromuscular diseases. Construction and validation study. *Neuromuscul Disord.* 2005;15:463-470.
11. Trundell D, Le Scouiller S, Servais L, et al. Using Rasch analysis to estimate thresholds associated with gain/loss of daily function on the Motor Function Measure (MFM). Poster presented at: 23rd International SMA Research Meeting; June 28-July 1, 2019; Anaheim, CA.
12. Mazzone ES, Mayhew A, Montes J, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. *Muscle Nerve.* 2017;55:869-874.

EVRYSDI IS PROVEN TO PROVIDE EFFICACY IN INFANTS, CHILDREN, AND ADULTS WITH SMA

Evaluated in a wide range of people with SMA^{1,6,8}

- The Evrysdi trial program includes 450+ patients who exhibit a broad range of disease severity and functional ability
- The first SMA trial program to include patients over 18 years of age, some of whom have severe scoliosis

Motor function improvements across 2 pivotal trials¹

Infants in FIREFISH (age range, 2-7 months)—the study of patients with Type 1 SMA (n=21 in Part 1):

- **41% of infants achieved the ability to sit without support** for at least 5 seconds, as measured by Item 22 on the BSID-III gross motor scale (recommended-dose cohort, n=7/17)
- **90% of infants were alive without the need for permanent ventilation** and reached ≥ 15 months of age (n=19/21 after 12 months of treatment)
- **81% of infants were alive without the need for permanent ventilation** and reached ≥ 28 months of age (n=17/21 after 23 months of treatment)

Children and adults in SUNFISH—the study of patients with Type 2 or Type 3 SMA (n=180 in Part 2; age range, 2-25 years):

- **Significant improvement in motor function with Evrysdi** (n=115) from baseline at 12 months vs placebo (n=59) in children and adults, as measured by MFM-32 (1.55-point difference between the means; 95% CI: 0.30, 2.81; $P=0.0156$)
 - Evrysdi demonstrated a 1.36-point mean change from baseline (95% CI: 0.61, 2.11) vs a -0.19-point mean change from baseline for placebo (95% CI: -1.22, 0.84)

Favorable benefit/risk profile evaluated across 3 clinical trials^{1,7}

- The safety profile of Evrysdi was studied in a wide range of infants, children, and adults with SMA

Indication

Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.

Important Safety Information

Avoid coadministration with drugs that are substrates of multidrug and toxin extrusion (MATE) transporters. Based on animal data, Evrysdi may cause fetal harm and may compromise male fertility. Avoid use in patients with hepatic impairment.

Please see accompanying full Prescribing Information for additional Important Safety Information.



HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use EVRYSDI safely and effectively. See full prescribing information for EVRYSDI.

EVRYSDI™ (risdiplam) for oral solution
Initial U.S. Approval: 2020

----- **INDICATIONS AND USAGE** -----

EVRYSDI is a survival of motor neuron 2 (SMN2) splicing modifier indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older. (1)

----- **DOSAGE AND ADMINISTRATION** -----

EVRYSDI must be constituted by a pharmacist prior to dispensing. Administer orally once daily after a meal using the provided oral syringe. (2.1, 2.4)

Age and Body Weight	Recommended Daily Dosage
2 months to less than 2 years of age	0.2 mg/kg
2 years of age and older weighing less than 20 kg	0.25 mg/kg
2 years of age and older weighing 20 kg or more	5 mg

See Full Prescribing Information for important preparation and administration instructions. (2.1, 2.4)

----- **DOSAGE FORMS AND STRENGTHS** -----

For Oral Solution: 60 mg of risdiplam as a powder for constitution to provide 0.75 mg/mL solution. (3)

----- **CONTRAINDICATIONS** -----

None. (4)

----- **ADVERSE REACTIONS** -----

The most common adverse reactions in later-onset SMA (incidence at least 10% of patients treated with EVRYSDI and more frequent than control) were fever, diarrhea, and rash. (6.1)

The most common adverse reactions in infantile-onset SMA were similar to those observed in later-onset SMA patients. Additionally, adverse reactions with an incidence of at least 10% were upper respiratory tract infection, pneumonia, constipation, and vomiting. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

----- **DRUG INTERACTIONS** -----

Avoid coadministration with drugs that are substrates of multidrug and toxin extrusion (MATE) transporters. (7.1)

----- **USE IN SPECIFIC POPULATIONS** -----

Pregnancy: Based on animal data, may cause fetal harm. (8.1)

Hepatic Impairment: Avoid use in patients with hepatic impairment. (8.6)

See 17 for **PATIENT COUNSELING INFORMATION** and **FDA-approved patient labeling**.

Revised: 8/2020

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Important Administration Instructions
- 2.2 Dosing Information
- 2.3 Missed Dose
- 2.4 Preparation of Oral Solution by Pharmacists

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience

7 DRUG INTERACTIONS

- 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Hepatic Impairment

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES

- 14.1 Infantile-Onset SMA
- 14.2 Later-Onset SMA

16 HOW SUPPLIED/STORAGE AND HANDLING

- 16.1 How Supplied
- 16.2 Storage and Handling

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

EVERYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.

2 DOSAGE AND ADMINISTRATION

2.1 Important Administration Instructions

Dose Preparation

It is recommended that a healthcare provider discuss with the patient or caregiver how to prepare the prescribed daily dose prior to administration of the first dose [*see Instructions for Use*].

Instruct patients or caregivers to prepare the dose using the reusable oral syringe provided.

EVERYSDI must be taken immediately after it is drawn up into the oral syringe. If EVRYSDI is not taken within 5 minutes, EVRYSDI should be discarded from the oral syringe, and a new dose should be prepared.

Dose Administration

EVERYSDI is taken orally once daily after a meal at approximately the same time each day.

In infants who are breastfed, EVRYSDI should be administered after breastfeeding. EVRYSDI cannot be mixed with formula or milk.

Instruct patients to drink water after taking EVRYSDI to ensure the drug has been completely swallowed.

If the patient is unable to swallow and has a nasogastric or gastrostomy tube, EVRYSDI can be administered via the tube. The tube should be flushed with water after delivering EVRYSDI [*see Instructions for Use*].

2.2 Dosing Information

EVERYSDI is administered orally once daily. The recommended dosage is determined by age and body weight (see Table 1).

Table 1 Adult and Pediatric Dosing Regimen by Age and Body Weight

Age and Body Weight	Recommended Daily Dosage
2 months to less than 2 years of age	0.2 mg/kg
2 years of age and older weighing less than 20 kg	0.25 mg/kg
2 years of age and older weighing 20 kg or more	5 mg

2.3 Missed Dose

If a dose of EVRYSDI is missed, EVRYSDI should be administered as soon as possible if still within 6 hours of the missed dose, and the usual dosing schedule can be resumed on the next day. Otherwise, the missed dose should be skipped, and the next dose should be taken at the regularly scheduled time on the next day.

If a dose is not fully swallowed or vomiting occurs after taking a dose of EVRYSDI, another dose should not be administered to make up for the lost dose. The patient should wait until the next day to take the next dose at the regularly scheduled time.

2.4 Preparation of Oral Solution by Pharmacists

EVRYSDI powder must be constituted to the oral solution by a pharmacist prior to dispensing to the patient.

Preparation of the EVRYSDI Oral Solution 0.75 mg/mL

The EVRYSDI “Instructions for Constitution” booklet contains more detailed instructions on the preparation of the oral solution [*see Instructions for Constitution*].

Caution should be exercised in the handling of EVRYSDI powder for oral solution. Avoid inhalation and direct contact with skin or mucous membranes with the dry powder and the constituted solution. If such contact occurs, wash thoroughly with soap and water; rinse eyes with water. Wear disposable gloves during the preparation and cleanup procedure.

1. Gently tap the bottom of the closed glass bottle to loosen the powder.
2. Remove the cap. Do not throw away the cap.
3. Carefully pour 79 mL of Purified Water into the EVRYSDI bottle to yield the 0.75 mg/mL oral solution. Do not mix EVRYSDI with formula or milk.
4. Insert the Press-In bottle adapter into the bottle opening by pushing it down against the bottle lip. Ensure it is completely pressed against the bottle lip.
5. Re-cap the bottle tightly and shake well for 15 seconds. Wait for 10 minutes. You should have obtained a clear solution. If not, shake well again for another 15 seconds.
6. Write the date of expiration of the constituted oral solution (calculated as 64 days after constitution) and the lot number on the bottle label. Peel off the part of the bottle label that has the expiration date of the powder.
7. Put the bottle back in its original carton.
8. Select the appropriate oral syringes (6 mL or 12 mL) based on the patient’s dosage and remove the other oral syringes from the carton.
9. Dispense with the “Instructions for Use” and FDA-approved patient labeling. Alert patients to read the important handling information described in the Instructions for Use.

Keep the constituted oral solution of EVRYSDI in the original amber bottle to protect from light. Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Discard any unused portion 64 days after constitution. Keep the bottle in an upright position with the cap tightly closed.

3 DOSAGE FORMS AND STRENGTHS

EVRYSDI for oral solution: 60 mg as a light yellow, yellow, greyish yellow, greenish yellow, or light green powder for constitution. Following constitution, the volume of the greenish yellow to yellow solution is 80 mL, providing 60 mg/80 mL (0.75 mg/mL) risdiplam.

4 CONTRAINDICATIONS

None.

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.

In clinical trials including patients with infantile-onset SMA and later-onset SMA, a total of 337 patients (52% female, 72% Caucasian) were exposed to EVRYSDI for up to a maximum of 32 months, with 209 patients receiving treatment for more than 12 months. Forty-seven (14%) patients were 18 years and older, 74 (22%) were 12 years to less than 18 years, 154 (46%) were 2 years to less than 12 years, and 62 (18%) 2 months to less than 2 years.

Clinical Trial in Later-Onset SMA

The safety of EVRYSDI for later-onset SMA is based on data from a randomized, double-blinded, placebo-controlled study (Study 2 Part 2) in patients with SMA Type 2 or 3 (n = 180) [see *Clinical Studies (14.2)*]. The patient population in Study 2 Part 2 ranged in age from 2 to 25 years at the time of treatment start.

The most common adverse reactions (reported in at least 10% of patients treated with EVRYSDI and at an incidence greater than on placebo) in Study 2 Part 2 were fever, diarrhea, and rash. Table 2 lists the adverse reactions that occurred in at least 5% of patients treated with EVRYSDI and at an incidence $\geq 5\%$ greater than on placebo in Study 2 Part 2.

Table 2 Adverse Reactions Reported in $\geq 5\%$ of Patients Treated with EVRYSDI and with an Incidence $\geq 5\%$ Greater Than on Placebo in Study 2 Part 2

Adverse Reaction	EVRYSDI (N = 120) %	Placebo (N = 60) %
Fever ¹	22	17
Diarrhea	17	8
Rash ²	17	2
Mouth and aphthous ulcers	7	0
Arthralgia	5	0
Urinary tract infection ³	5	0

¹ Includes pyrexia and hyperpyrexia.

² Includes rash, erythema, rash maculo-papular, rash erythematous, rash papular, dermatitis allergic, and folliculitis.

³ Includes urinary tract infection and cystitis.

Clinical Trial in Infantile-Onset SMA

The safety of EVRYSDI therapy for infantile-onset SMA is based on data from an open-label study in 62 patients (Study 1) [see *Clinical Studies (14.1)*]. In Study 1 Part 1 (n = 21) and Part 2 (n = 41), 62 patients received EVRYSDI for up to 30 months (31 patients for more than 12 months). The patient population ranged in age from 2 to 7 months at the time of treatment start (weight range 4.1 to 10.6 kg).

The most frequent adverse reactions reported in infantile-onset SMA patients treated with EVRYSDI in Study 1 were similar to those observed in later-onset SMA patients in Study 2. Additionally, the following adverse reactions were reported in $\geq 10\%$ of patients: upper respiratory tract infection (including nasopharyngitis, rhinitis, respiratory tract infection), pneumonia, constipation, and vomiting.

7 DRUG INTERACTIONS

7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters

Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see *Clinical Pharmacology (12.3)*], such as metformin. Avoid coadministration of EVRYSDI with MATE substrates. If coadministration cannot be avoided, monitor for drug-related toxicities and consider dosage reduction of the coadministered drug (based on the labeling of that drug) if needed.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no adequate data on the developmental risk associated with the use of EVRYSDI in pregnant women. In animal studies, administration of risdiplam during pregnancy or throughout pregnancy and lactation resulted in adverse effects on development (embryofetal mortality, malformations, decreased fetal body weights, and reproductive impairment in offspring) at or above clinically relevant drug exposures [see *Data*].

The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Based on animal data, advise pregnant women of the potential risk to the fetus.

Data

Animal Data

Oral administration of risdiplam (0, 1, 3, or 7.5 mg/kg) to pregnant rats throughout organogenesis resulted in decreased fetal body weights and increased incidences of fetal structural variations at the highest dose tested, which was not associated with maternal toxicity. The no-effect level for adverse effects on embryofetal development (3 mg/kg/day) was associated with maternal plasma exposure (AUC) approximately 2 times that in humans at the maximum recommended human dose (MRHD) of 5 mg.

Oral administration of risdiplam (0, 1, 4, or 12 mg/kg) to pregnant rabbits throughout organogenesis resulted in embryofetal mortality, fetal malformations (hydrocephaly), and structural variations at the highest dose tested, which was associated with maternal toxicity. The no-effect dose for adverse effects on embryofetal development (4 mg/kg/day) was associated with maternal plasma exposure (AUC) approximately 4 times that in humans at the MRHD.

When risdiplam (0, 0.75, 1.5, or 3 mg/kg/day) was orally administered to rats throughout pregnancy and lactation, gestation was prolonged in the dams, and delayed sexual maturation (vaginal opening) and impaired reproductive function (decreased numbers of corpora lutea, implantation sites, and live embryos) were observed in female offspring at the highest dose. The no-effect dose for adverse effects on pre- and postnatal development in rats (1.5 mg/kg/day) was associated with maternal plasma exposure (AUC) similar to that in humans at the MRHD.

8.2 Lactation

Risk Summary

There are no data on the presence of risdiplam in human milk, the effects on the breastfed infant, or the effects on milk production. Risdiplam was excreted in the milk of lactating rats orally administered risdiplam.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EVRYSDI and any potential adverse effects on the breastfed infant from EVRYSDI or from the underlying maternal condition.

8.3 Females and Males of Reproductive Potential

Studies of risdiplam in juvenile and adult rats and in monkeys demonstrated adverse effects on the reproductive organs, including germ cells, in males at clinically-relevant plasma exposures [*see Use in Specific Populations (8.4) and Nonclinical Toxicology (13.1)*].

Pregnancy Testing

Pregnancy testing is recommended for females of reproductive potential prior to initiating EVRYSDI [*see Use in Specific Populations (8.1)*].

Contraception

EVRYSDI may cause embryofetal harm when administered to a pregnant woman [*see Use in Specific Populations (8.1)*].

Female Patients

Advise female patients of reproductive potential to use effective contraception during treatment with EVRYSDI and for at least 1 month after her last dose.

Infertility

Male Patients

Male fertility may be compromised by treatment with EVRYSDI [*see Nonclinical Toxicology (13.1)*].

Counsel male patients of reproductive potential receiving EVRYSDI about the potential effects on fertility. Male patients may consider sperm preservation prior to treatment.

8.4 Pediatric Use

The safety and effectiveness of EVRYSDI in pediatric patients 2 months of age and older have been established [*see Clinical Studies (14)*]. Safety and effectiveness in pediatric patients below the age of 2 months have not been established [*see Clinical Pharmacology (12.3)*].

Juvenile Animal Toxicity Data

Oral administration of risdiplam (0, 0.75, 1.5, 2.5 mg/day) to young rats from postnatal day (PND) 4 through PND 31 resulted in decreased growth (body weight, tibia length) and delayed sexual maturation in males at the mid and high dose. The skeletal and body weight deficits persisted after cessation of dosing. Ophthalmic changes consisting of vacuoles in the anterior vitreous were seen at the high dose. Decreases in absolute B lymphocyte counts were observed at all doses after cessation of dosing. Decreases in testis and epididymis weights, which correlated with degeneration of the seminiferous epithelium in the testis, occurred at the mid and high doses; the histopathology findings were reversible, but organ weight persisted after cessation of dosing. Impaired female reproductive performance (decreased mating index, fertility index, and conception rate) was observed at the high dose. A no-effect dose for adverse developmental effects on preweaning rats was not identified. The lowest dose tested (0.75 mg/kg/day) was associated with plasma exposures (AUC) lower than that in humans at the maximum recommended human dose (MRHD) of 5 mg/day.

Oral administration of risdiplam (0, 1, 3, or 7.5 mg/day) to young rats from PND 22 through PND 112 produced a marked increase in micronuclei in the bone marrow, male reproductive organ histopathology (degeneration/necrosis of the seminiferous tubule epithelium,

oligo/aspermia in the epididymis, spermatic granulomas), and adverse effects on sperm parameters (decreased sperm concentration and motility, increased sperm morphology abnormalities) at the highest dose tested. Increases in T lymphocytes (total, helper, and cytotoxic) were observed at the mid and high doses. The reproductive and immune effects persisted after cessation of dosing. The no-effect dose (1 mg/kg/day) for adverse effects on postweaning juvenile rats was associated with plasma exposures (AUC) lower than that in humans at the MRHD.

8.5 Geriatric Use

Clinical studies of EVRYSDI did not include patients aged 65 years and over to determine whether they respond differently from younger patients.

8.6 Hepatic Impairment


The safety and efficacy of EVRYSDI in patients with hepatic impairment have not been studied. Because risdiplam is predominantly metabolized in the liver, hepatic impairment may potentially increase the exposures to risdiplam [see *Clinical Pharmacology (12.3)*]. Avoid use of EVRYSDI in patients with impaired hepatic function.

11 DESCRIPTION

EVRYSDI for oral solution contains risdiplam, which is a survival of motor neuron 2 (SMN2)-directed RNA splicing modifier.

The chemical name of risdiplam is 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido-4H-[1,2-a]pyrimidin-4-one. Risdiplam has a molecular weight of 401.46 g/mol.

The molecular formula of risdiplam is C₂₂H₂₃N₇O and the chemical structure is shown below.



EVRYSDI is supplied as a powder in an amber glass bottle. Each bottle contains 60 mg of risdiplam. The inactive ingredients of EVRYSDI are: ascorbic acid, disodium edetate dihydrate, isomalt, mannitol, polyethylene glycol 6000, sodium benzoate, strawberry flavor, sucralose, and tartaric acid.

The powder is constituted with purified water to yield 60 mg/80 mL (0.75 mg/mL) of risdiplam after constitution [see *Dosage and Administration (2.4)*].

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Risdiplam is a survival of motor neuron 2 (SMN2) splicing modifier designed to treat patients with spinal muscular atrophy (SMA) caused by mutations in chromosome 5q that lead to SMN protein deficiency. Using in vitro assays and studies in transgenic animal models of SMA, risdiplam was shown to increase exon 7 inclusion in SMN2 messenger ribonucleic acid (mRNA) transcripts and production of full-length SMN protein in the brain.

In vitro and in vivo data indicate that risdiplam may cause alternative splicing of additional genes, including FOXM1 and MADD. FOXM1 and MADD are thought to be involved in cell

cycle regulation and apoptosis, respectively, and have been identified as possible contributors to adverse effects seen in animals.

12.2 Pharmacodynamics

In clinical trials, EVRYSDI led to an increase in SMN protein with a greater than 2-fold median change from baseline within 4 weeks of treatment initiation. The increase was sustained throughout the treatment period (of at least 12 months) across all SMA types.

12.3 Pharmacokinetics

Pharmacokinetics of EVRYSDI have been characterized in healthy adult subjects and in patients with SMA.

After administration of EVRYSDI as an oral solution, pharmacokinetics of risdiplam were approximately linear between 0.6 and 18 mg in a single-ascending-dose study in healthy adult subjects, and between 0.02 and 0.25 mg/kg once daily in a multiple-ascending-dose study in patients with SMA. Following once-daily oral administration of risdiplam in healthy subjects, approximately 3-fold accumulation of peak plasma concentrations (C_{max}) and area under the plasma concentration-time curve (AUC_{0-24h}) was observed. Risdiplam exposures reach steady state 7 to 14 days after once-daily administration.

Absorption

Following oral administration, the time to reach maximum plasma concentration (T_{max}) is between 1 and 4 hours.

Effect of Food

In the clinical efficacy studies (Study 1 and Study 2), risdiplam was administered with a morning meal or after breastfeeding.

Distribution

The apparent volume of distribution at steady state is 6.3 L/kg.

Risdiplam is predominantly bound to serum albumin, without any binding to alpha-1 acid glycoprotein, with a free fraction of 11%.

Elimination

The apparent clearance (CL/F) of risdiplam is 2.1 L/h for a 14.9 kg patient.

The terminal elimination half-life of risdiplam was approximately 50 hours in healthy adults.

Metabolism

Risdiplam is primarily metabolized by flavin monooxygenase 1 and 3 (FMO1 and FMO3) and also by CYPs 1A1, 2J2, 3A4, and 3A7.

Parent drug was the major component found in plasma, accounting for 83% of drug-related material in circulation. The pharmacologically-inactive metabolite M1 was identified as the major circulating metabolite.

Excretion

Following a dose of 18 mg, approximately 53% of the dose (14% unchanged risdiplam) was excreted in the feces and 28% in urine (8% unchanged risdiplam).

Specific Populations

There were no clinically significant differences in the pharmacokinetics of EVRYSDI based on race or gender. Renal impairment is not expected to alter the exposures to risdiplam.

The impact of geriatric age and hepatic impairment on the pharmacokinetics of EVRYSDI has not been studied.

Pediatric Patients

Body weight and age were found to have significant effect on the pharmacokinetics of risdiplam. The estimated exposure (mean AUC_{0-24h}) for infantile-onset SMA patients (age 2 to 7 months at enrollment) at the recommended dose of 0.2 mg/kg once daily was 1930 ng.h/mL. The estimated exposure for later-onset SMA patients (2 to 25 years old at enrollment) at the recommended dose was 2050 ng.h/mL (0.25 mg/kg once daily for patients with a body weight < 20 kg and 5 mg once daily for patients with a body weight \geq 20 kg). The observed maximum concentration (mean C_{max}) was 184 ng/mL for infantile-onset SMA patients and 148 ng/mL for later-onset SMA patients.

Based on literature reports, pediatric patients less than 2 months of age are expected to have reduced activity of FMO3, which may result in increased exposure to risdiplam [see *Elimination*]. No data on risdiplam pharmacokinetics are available in patients less than 2 months of age [see *Use in Specific Populations (8.4)*].

Drug Interaction Studies

Effect of Other Drugs on EVRYSDI

Coadministration of 200 mg itraconazole (a strong CYP3A inhibitor) twice daily with a single 6 mg oral dose of risdiplam did not have a clinically relevant effect on the pharmacokinetics of risdiplam (11% increase in AUC and 9% decrease in C_{max}).

Risdiplam is a weak substrate of human MDR-1 and breast cancer resistant protein (BCRP) transporters in vitro. Human MDR-1 or BCRP inhibitors are not expected to result in a clinically significant increase of risdiplam concentrations.

Effect of EVRYSDI on Other Drugs

Risdiplam and its major circulating metabolite M1 did not induce CYP1A2, 2B6, 2C8, 2C9, 2C19, or 3A4 in vitro. Risdiplam and M1 did not inhibit (reversible or time-dependent inhibition) any of the CYP enzymes tested (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6), with the exception of CYP3A in vitro.

EVRYSDI is a weak inhibitor of CYP3A. In healthy adult subjects, administration of EVRYSDI once daily for 2 weeks slightly increased the exposure of midazolam, a sensitive CYP3A substrate (AUC 11%; C_{max} 16%); this increase is not considered clinically relevant. Based on physiologically-based pharmacokinetic (PBPK) modeling, a similar increase is expected in children and infants as young as 2 months of age.

In vitro studies have shown that risdiplam and its major metabolite are not significant inhibitors of human MDR1, organic anion-transporting polypeptide (OATP) 1B1, OATP1B3, organic anion transporter 1 and 3 (OAT 1 and 3) transporters, and human organic cation transporter 2 (OCT2), at clinically relevant concentrations. Risdiplam and its metabolite are, however, in vitro inhibitors of the multidrug and toxin extrusion (MATE) 1 and MATE2-K transporters [see *Drug Interactions (7.1)*].

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

The carcinogenic potential of risdiplam has not been fully evaluated. Risdiplam was not carcinogenic in Tg.rasH2 mice when administered at oral doses of up to 9 mg/kg/day for 26 weeks.

Mutagenesis

Risdiplam was negative in an in vitro Ames assay. In an in vivo combined bone marrow micronucleus and comet assay in rat, risdiplam was clastogenic, as evidenced by an increase in micronuclei in bone marrow, but was negative in the comet assay. A pronounced increase in bone marrow micronuclei was also observed in toxicity studies in adult and juvenile rats [*see Use in Specific Populations (8.4)*].

Impairment of Fertility

Oral administration of risdiplam to rats for 4 (0, 1, 3, or 9 mg/kg/day) or 26 (0, 1, 3, or 7.5 mg/kg/day) weeks resulted in histopathological effects in the testis (degenerated spermatocytes, degeneration/atrophy of the seminiferous tubules) and epididymis (degeneration/necrosis of ductular epithelium) at the mid and/or high doses. At the high dose in the 26-week study, the testicular lesions persisted to the end of the recovery period, which corresponds, in rat, to approximately one spermatogenic cycle. The no-effect dose for adverse reproductive system effects in adult male rats (1 mg/kg/day) was associated with plasma drug exposures (AUC) similar to that in humans at the maximum recommended human dose (MRHD) of 5 mg/day.

Adverse effects of risdiplam on the testis could not be fully evaluated in the monkey because the majority of monkeys tested were sexually immature. However, oral administration of risdiplam (0, 2, 4, or 6 mg/kg/day) for 2 weeks resulted in histopathological changes in the testis (increases in multinucleate cells, germ cell degeneration) at the highest dose. At the no-effect dose for testicular toxicity in monkeys, plasma exposures were approximately 3 times that in humans at the MRHD.

Oral administration of risdiplam to postweaning juvenile rats resulted in male reproductive toxicity (degeneration/necrosis of the testis seminiferous epithelium with associated oligo/aspermia in the epididymis and abnormal sperm parameters). The no-effect dose for adverse reproductive effects in postweaning male juvenile rats was associated with plasma exposures approximately 4 times that in humans at the MRHD [*see Use in Specific Populations (8.4)*].

13.2 Animal Toxicology and/or Pharmacology

Retinal toxicity

Risdiplam-induced functional and structural retinal abnormalities were seen in animal studies. In a 39-week toxicity study in monkeys, oral administration of risdiplam (0, 1.5, 3, or 7.5/5 mg/kg/day; high dose lowered after 4 weeks) produced functional abnormalities on the electroretinogram (ERG) in all mid- and high-dose animals at the earliest examination time (Week 20). These findings were associated with retinal degeneration, detected by optical coherence tomography (OCT), on Week 22, the first examination time. The retinal degeneration, with peripheral photoreceptor loss, was irreversible. A no-effect dose for the retinal findings (1.5 mg/kg/day) was associated with plasma exposures (AUC) similar to that in humans at the maximum recommended human dose (MRHD) of 5 mg.

Effect on Epithelial Tissues

Oral administration of risdiplam to rats and monkeys resulted in histopathological changes in epithelium of the gastrointestinal (GI) tract (apoptosis/single cell necrosis), lamina propria (vacuolation), the exocrine pancreas (single cell necrosis), the skin, tongue, and larynx

(parakeratosis/hyperplasia/degeneration) with associated inflammation. The skin and GI epithelial effects were reversible. The no-effect doses for effects on epithelial tissues in rats and monkeys were associated with plasma exposures (AUC) similar to that in humans at the MRHD.

14 CLINICAL STUDIES

The efficacy of EVRYSDI for the treatment of patients with infantile-onset and later-onset SMA was evaluated in two clinical studies, Study 1 (NCT02913482) and Study 2 (NCT02908685).

The overall findings of these studies support the effectiveness of EVRYSDI in SMA patients 2 months of age and older and appear to support the early initiation of treatment with EVRYSDI.

14.1 Infantile-Onset SMA

Study 1 was an open-label, 2-part study to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of EVRYSDI in patients with Type 1 SMA (symptom onset between 28 days and 3 months of age). Part 1 of Study 1 (n = 21) provides efficacy and safety data in patients with Type 1 SMA. Additional safety information is provided by Part 2 of Study 1 (n = 41) in patients with Type 1 SMA [see *Adverse Reactions (6.1)*].

In Part 1 of Study 1, patients (n = 21) were enrolled in one of two dosage cohorts. Patients in the higher-dosage cohort (n = 17) had their dosage adjusted to the recommended dosage of 0.2 mg/kg/day before 12 months of treatment, while patients in the low-dosage cohort (n = 4) did not.

Effectiveness was established based on the ability to sit without support for at least 5 seconds (as measured by Item 22 of the Bayley Scales of Infant and Toddler Development – Third Edition (BSID-III) gross motor scale) and on the basis of survival without permanent ventilation. Permanent ventilation was defined as requiring a tracheostomy or more than 21 consecutive days of either non-invasive ventilation (≥ 16 hours per day) or intubation, in the absence of an acute reversible event.

The median age of onset of clinical signs and symptoms of Type 1 SMA in patients enrolled in Part 1 of Study 1 was 2.0 months (range: 0.9 to 3.0); 71% of patients were female, 81% were Caucasian, and 19% were Asian. The median age at enrollment was 6.7 months (range: 3.3 to 6.9), and the median time between onset of symptoms and first dose was 4.0 months (range: 2.0 to 5.8). All patients had genetic confirmation of homozygous deletion or compound heterozygosity predictive of loss of function of the SMN1 gene, and two SMN2 gene copies.

In Study 1 Part 1, the median duration of EVRYSDI treatment was 14.8 months (range: 0.6 to 26.0), and 19 patients were treated for a minimum duration of 12 months.

Of the patients who were treated with the recommended dosage of EVRYSDI 0.2 mg/kg/day, 41% (7/17) were able to sit independently for ≥ 5 seconds (BSID-III, Item 22) after 12 months of treatment. These results indicate a clinically meaningful deviation from the natural history of untreated infantile-onset SMA. As described in the natural history of untreated infantile-onset SMA, patients would not be expected to attain the ability to sit independently, and no more than 25% of these patients would be expected to survive without permanent ventilation beyond 14 months of age. After 12 months of treatment with EVRYSDI, 90% (19/21) of patients were alive without permanent ventilation (and reached 15 months of age or older). After a minimum of 23 months of treatment with EVRYSDI, 81% (17/21) of all patients were alive without permanent ventilation (and reached an age of 28 months or older; median 32 months; range 28 to 45 months).

14.2 Later-Onset SMA

Study 2 was a 2-part, multicenter trial to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of EVRYSDI in patients diagnosed with SMA Type 2 or Type 3. Part 1 of

Study 2 was dose-finding and exploratory in 51 patients (14% ambulatory). Part 2 was randomized, double-blind, placebo-controlled, and is described below.

The primary endpoint in Study 2 Part 2 was the change from baseline to Month 12 in the Motor Function Measure 32 (MFM32) score. A key secondary endpoint was the proportion of patients with a 3-point or greater change from baseline to Month 12 in the MFM32 total score. The MFM32 measures motor function abilities that relate to daily functions. The total MFM32 score is expressed as a percentage (range: 0 to 100) of the maximum possible score, with higher scores indicating greater motor function. Another key secondary endpoint was the Revised Upper Limb Module (RULM). The RULM is a tool used to assess motor performance of the upper limb in SMA patients. It tests proximal and distal motor functions of the arm. The total score ranges from 0 (all the items cannot be performed) to 37 (all the activities are achieved fully without any compensatory maneuvers).

Study 2 Part 2 enrolled 180 non-ambulatory patients with Type 2 (71%) or Type 3 (29%) SMA. Patients were randomized 2:1 to receive EVRYSDI at the recommended dosage [*see Dosage and Administration (2.2)*] or placebo. Randomization was stratified by age group (2 to 5, 6 to 11, 12 to 17, or 18 to 25 years of age).

The median age of patients at the start of treatment was 9.0 years (range 2 to 25), and the median time between onset of initial SMA symptoms and first treatment was 102.6 months (range 1 to 275). Of the 180 patients included in the trial, 51% were female, 67% were Caucasian, and 19% were Asian. At baseline, 67% of patients had scoliosis (32% of them with severe scoliosis). Patients had a mean baseline MFM32 score of 46.1, and RULM score of 20.1. Overall baseline demographic characteristics were reasonably balanced between the treatment groups (EVRYSDI and placebo), with the exception of scoliosis (63% in the EVRYSDI arm vs. 73% in the placebo group).


The primary analysis on the change from baseline in MFM32 total score at Month 12 showed a clinically meaningful and statistically significant difference between patients treated with EVRYSDI and placebo. The results of the primary analysis and key secondary endpoints are shown in Table 3 and Figure 1.

Table 3 Summary of Efficacy in Patients with Later-Onset SMA at Month 12 of Treatment (Study 2 Part 2)

Endpoint	EVRYSDI (N = 120)	Placebo (N = 60)
Primary Endpoint:		
Change from baseline in total MFM32 score at Month 12, LS means (95% CI) ^{1,2,3}	1.36 (0.61, 2.11)	-0.19 (-1.22, 0.84)
Difference from Placebo, Estimate (95% CI) ¹ p-value	1.55 (0.30, 2.81) 0.0156	
Secondary Endpoints:		
Proportion of patients with a change from baseline MFM32 total score of 3 or more at Month 12 (95% CI) ^{2,3}	38.3% (28.9, 47.6)	23.7% (12.0, 35.4)
Odds ratio for overall response (95% CI) adjusted ⁴ (unadjusted) p-value ⁵	2.35 (1.01, 5.44) 0.0469 (0.0469)	
Change from baseline in total score of RULM at Month 12, LS means (95% CI) ^{1, 6}	1.61 (1.00, 2.22)	0.02 (-0.83, 0.87)
Difference from Placebo, Estimate (95% CI) adjusted ⁴ (unadjusted) p-value ¹	1.59 (0.55, 2.62) 0.0469 (0.0028)	

- ¹. The Mixed Model Repeated Measure (MMRM) analysis included the change from baseline total score as the dependent variable and as independent variables the baseline total score, treatment group, time, treatment-by-time interaction, and the randomization stratification variable of age group (2 to 5, 6 to 11, 12 to 17, 18 to 25).
- ². The MFM total score was calculated according to the user manual, expressed as a percentage of the maximum score possible for the scale (i.e., sum of the 32 item scores divided by 96 and multiplied by 100).
- ³. Based on the missing data rule for MFM32, 6 patients were excluded from the analysis (EVRYSDI n = 115; placebo control n = 59).
- ⁴. The adjusted p-value was obtained for the endpoints included in the hierarchical testing and was derived based on all the p-values from endpoints in order of the hierarchy up to the current endpoint.
- ⁵. The logistic regression analysis included the baseline total score, treatment and age group as independent variables.
- ⁶. Based on the missing data rule for RULM, 3 patients were excluded from the analysis (EVRYSDI n = 119; placebo control n = 58).

Figure 1 Mean Change from Baseline in Total MFM32 Score Over 12 Months (Study 2 Part 2)^{1,2}



¹ Error bars denote the 95% confidence interval.

² The MFM total score was calculated according to the user manual, expressed as a percentage of the maximum score possible for the scale (i.e., sum of the 32 item scores divided by 96 and multiplied by 100).

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Each amber glass bottle of EVRYSDI is packaged with a bottle adapter, two 6 mL reusable oral syringes, and two 12 mL reusable oral syringes. EVRYSDI for oral solution is a light yellow, yellow, greyish yellow, greenish yellow, or light green powder. Each bottle contains 60 mg of risdiplam (NDC 50242-175-07).

16.2 Storage and Handling

Store the dry powder at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP controlled room temperature]. Keep in the original carton.

Keep the constituted oral solution of EVRYSDI in the original amber bottle to protect from light. Store in a refrigerator at 2°C to 8°C (36°F to 46°F) [see *Dosage and Administration (2.4)*].

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Pregnancy and Fetal Risk

Inform pregnant women and women of reproductive potential that, based on animal studies, EVRYSDI may cause fetal harm [see *Use in Specific Populations (8.1)*].

Discuss with women of childbearing age whether they are pregnant, might be pregnant, or are trying to become pregnant.

Advise women of childbearing potential to use effective contraception during treatment with EVRYSDI and for at least 1 month after stopping EVRYSDI.

Advise a female patient to immediately inform the prescriber if she is pregnant or planning to become pregnant [*see Use in Specific Populations (8.3)*].

Potential Effects on Male Fertility

Advise male patients that their fertility may be compromised while on treatment with EVRYSDI [*see Use in Specific Populations (8.3)*].

Instructions for Preparation of Oral Solution

Advise patients to ensure that EVRYSDI is in liquid form when received from the pharmacy.

Instruct patients/caregivers to take EVRYSDI after a meal or after breastfeeding at approximately the same time each day. However, instruct caregivers to not mix EVRYSDI with formula or milk.

Instruct patients/caregivers to take EVRYSDI immediately after it is drawn up into the reusable oral syringe [*see Dosage and Administration (2.1)*].

EVRYSDI™ [risdiplam]

Distributed by:

Genentech, Inc.

A Member of the Roche Group

1 DNA Way

South San Francisco, CA 94080-4990

EVRYSDI is a trademark of Genentech, Inc.

©2020 Genentech, Inc. All rights reserved.

Patient Information
EVERYSDI™ [ev-RIZ-dee]
(risdiplam)
for oral solution

What is EVERYSDI?

- EVERYSDI is a prescription medicine used to treat spinal muscular atrophy (SMA) in adults and children 2 months of age and older.
- It is not known if EVERYSDI is safe and effective in children under 2 months of age.

Before taking EVERYSDI, tell your healthcare provider about all of your medical conditions, including if you:

- have liver problems.
- are pregnant or plan to become pregnant. If you are pregnant, or are planning to become pregnant, ask your healthcare provider for advice before taking this medicine. EVERYSDI may harm your unborn baby.
- are a woman who can become pregnant:
 - Before you start your treatment with EVERYSDI, your healthcare provider may test you for pregnancy. Because EVERYSDI may harm your unborn baby, you and your healthcare provider will decide if taking EVERYSDI is right for you during this time.
 - Talk to your healthcare provider about birth control methods that may be right for you. Use birth control while on treatment and for at least 1 month after stopping EVERYSDI.
- are an adult male planning to have children: EVERYSDI may affect a man's ability to have children (fertility). If this is of concern to you, make sure to ask a healthcare provider for advice.
- are breastfeeding or plan to breastfeed. It is not known if EVERYSDI passes into breast milk and may harm your baby. If you plan to breastfeed, discuss with your healthcare provider about the best way to feed your baby while on treatment with EVERYSDI.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I take EVERYSDI?

See the detailed Instructions for Use that comes with EVERYSDI for information on how to take or give EVERYSDI oral solution.

- You should receive EVERYSDI from the pharmacy as a liquid that can be given by mouth or through a feeding tube. The liquid solution is prepared by your pharmacist. If the medicine in the bottle is a powder, **do not use it**. Contact your pharmacist for a replacement.
- Avoid getting EVERYSDI on your skin or in your eyes. If EVERYSDI gets on your skin, wash the area with soap and water. If EVERYSDI gets in your eyes, rinse your eyes with water.

Taking EVERYSDI

- Your healthcare provider will tell you how long you or your child needs to take EVERYSDI. Do not stop treatment with EVERYSDI unless your healthcare provider tells you to.
- For infants and children, your healthcare provider will determine the daily dose of EVERYSDI needed based on your child's age and weight. For adults, take 5 mg of EVERYSDI daily.
 - Take EVERYSDI exactly as your healthcare provider tells you to take it. Do not change the dose without talking to your healthcare provider.
- Take EVERYSDI 1 time daily after a meal (or after breastfeeding for a child) at approximately the same time each day. Drink water afterwards to make sure EVERYSDI has been completely swallowed.
- Do not mix EVERYSDI with formula or milk.
- If you are unable to swallow and have a nasogastric or gastrostomy tube, EVERYSDI can be given through the tube.
- If you miss a dose of EVERYSDI:
 - If you remember the missed dose within 6 hours of when you normally take EVERYSDI, then take or give the dose. Continue taking EVERYSDI at your usual time the next day.
 - If you remember the missed dose more than 6 hours after you normally take EVERYSDI, skip the missed dose. Take your next dose at your usual time the next day.
- If you do not fully swallow the dose, or you vomit after taking a dose, **do not take** another dose of EVERYSDI to make up for that dose. Wait until the next day to take the next dose at your usual time.

Reusable Oral Syringes

- Your pharmacist will provide you with the reusable oral syringes that are needed for taking your medicine and explain how to use them. Wash the syringes per instructions after use. Do not throw them away.
- Use the reusable oral syringes provided by your pharmacist (you should receive 2 identical oral syringes) to measure your or your child's dose of EVRYSDI, as they are designed to protect the medicine from light. Contact your healthcare provider or pharmacist if your oral syringes are lost or damaged.
- Once transferred from the bottle to the oral syringe, take EVRYSDI right away. Do not store the EVRYSDI solution in the syringe. If EVRYSDI is not taken within 5 minutes of when it is drawn up, EVRYSDI should be thrown away from the reusable oral syringe, and a new dose should be prepared.

What are the possible side effects of EVRYSDI?

The most common side effects of EVRYSDI include:

- **For later-onset SMA:**
 - fever
 - diarrhea
 - rash
- **For infantile-onset SMA:**
 - fever
 - runny nose, sneezing, sore throat, and cough (upper respiratory infection)
 - constipation
 - diarrhea
 - lung infection
 - vomiting
 - rash

These are not all of the possible side effects of EVRYSDI. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store EVRYSDI?

- Store EVRYSDI in the refrigerator between 36°F to 46°F (2°C to 8°C). Do not freeze.
- Keep EVRYSDI in an upright position in the original amber bottle to protect from light.
- Throw away (discard) any unused portion of EVRYSDI 64 days after it is mixed by the pharmacist (constitution). Please see the Discard After date written on the bottle label. (See the **Instructions for Use** that comes with EVRYSDI).

Keep EVRYSDI and all medicines out of the reach of children.

General information about the safe and effective use of EVRYSDI.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use EVRYSDI for a condition for which it was not prescribed. Do not give EVRYSDI to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about EVRYSDI that is written for health professionals.

What are the ingredients in EVRYSDI?

Active ingredient: risdiplam

Inactive ingredients: ascorbic acid, disodium edetate dihydrate, isomalt, mannitol, polyethylene glycol 6000, sodium benzoate, strawberry flavor, sucralose, and tartaric acid.

Distributed by: **Genentech, Inc.**, A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990

EVRYSDI is a trademark of Genentech, Inc.

©2020 Genentech, Inc. All rights reserved.

For more information, go to www.EVRYSDI.com or call 1-833-387-9734.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Approved: 8/2020